Scott Tykodi

Fred Hutchinson Cancer Research Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (7)

Year:

2025

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (8)

Nizar M Tannir

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Gerald Falchook

UNITED STATES

View details

Michael Gordon

Chief Medical Officer

UNITED STATES

View details

Edus Warren

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

Shreeram Akilesh

Associate Professor

University of Washington

UNITED STATES

View details

Jennifer Johansen

Head of Medical Affairs, The Americas

UNITED STATES

View details

Mohamed Gouda

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Scott Tykodi

Research Interests

Explore related searches

Contact this professor

Articles (7)

A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer

Telemedicine for Multidisciplinary Urologic Cancer Care: A Prospective Single Institution Study

Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip system

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial

Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma

Collaborators (8)

Nizar M Tannir

Gerald Falchook

Michael Gordon

Edus Warren

Shreeram Akilesh

Jennifer Johansen

Mohamed Gouda

Timothy Yap

Make your next move.